Currently, there are four monoclonal antibodies (mAbs) that target the cluster of
differentiation (CD) 20 receptor available to treat multiple sclerosis (MS): rituximab …

Anti-CD20 therapy to deplete B cells is highly efficacious in preventing new white matter
lesions in patients with relapsing-remitting multiple sclerosis (RRMS), but its protective …

Chronic low-grade inflammation and neuronal deregulation are two components of a
smoldering disease activity that drives the progression of disability in people with multiple …

Open-label extension (OLE) studies help inform long-term safety and efficacy of disease-
modifying therapies in multiple sclerosis (MS). We report exploratory analyses from a phase …

Ublituximab, an intravenous glycoengineered chimeric anti-CD20 IgG1 monoclonal
antibody (mAb), is a new FDA-approved treatment for relapsing forms of Multiple Sclerosis …

Most of the patients presenting with multiple sclerosis (MS) are in young or middle
adulthood. However, approximately 5% have pediatric-onset MS (POMS), and with …

Background: Ocrelizumab (OCR) is an anti-CD20 monoclonal antibody approved for the
treatment of relapsing-remitting and primary-progressive multiple sclerosis (MS). We aimed …

Objective The wearing-off phenomenon is common in people with multiple sclerosis (MS)
treated with ocrelizumab. We aim to evaluate the presence and severity of wearing-off to …

In clinical development, it is useful to characterize the causal relationship between individual
drug concentrations and clinical outcomes in large phase III trials of new therapeutic agents …

Background: This study investigates clinical and biomarker differences between standard
interval dosing (SID) and extended interval dosing (EID) of ocrelizumab therapy in multiple …